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Leptin inhibits insulin secretion induced by cellular
cAMP in a pancreatic B cell line (INS-1 cells)
BO AHRE´N1 AND PETER J. HAVEL2
1Department of Medicine, Lund University, Malmo¨, SE-205 02 Sweden;
and 2Department of Nutrition, University of California, Davis, California 95616
Ahre´n, Bo, and Peter J. Havel. Leptin inhibits insulin
secretion induced by cellular cAMP in a pancreatic B cell line
(INS-1 cells). Am. J. Physiol. 277 (Regulatory Integrative
Comp. Physiol. 46): R959–R966, 1999.—The effect of leptin
on insulin secretion is controversial due to conflicting results
in the literature. In the present study, we incubated insulin-
producing rat insulinoma INS-1 cells for 60 min and exam-
ined the effects of recombinant murine leptin (20 nmol/l). We
found that leptin (0.1–100 nmol/l) did not affect the insulin
response to glucose (1–20 mmol/l). However, when cells were
incubated with agents that increase the intracellular content
of cAMP, i.e., glucagon-like peptide-1 (100 nmol/l), pituitary
adenylate cyclase activating polypeptide (100 nmol/l), forsko-
lin (2.5 µmol/l), dibutyryl-cAMP (1 mmol/l), or 3-isobutyl-1-
methylxanthine (100 µmol/l), leptin significantly reduced
insulin secretion (by 34–58%, P , 0.05–0.001). In contrast,
when insulin secretion was stimulated by the cholinergic
agonist carbachol (100 µmol/l) or the phorbol ester 12-O-
tetradecanoylphorbol 13-acetate (1 µmol/l), both of which
activate protein kinase C, leptin was without effect. We
conclude that leptin inhibits insulin secretion from INS-1
cells under conditions in which intracellular cAMP is in-
creased. This suggests that the cAMP-protein kinase A signal
transduction pathway is a target for leptin to inhibit insulin
secretion in insulin-producing cells.
glucagon-like peptide-1; pituitary adenylate cyclase activat-
ing polypeptide-38; forskolin; adenosine 38,58-cyclic monophos-
phate; 3-isobutyl-1-methylxanthine; carbachol; protein ki-
nase C; calcium
LEPTIN IS EXPRESSED in adipocytes and secreted into the
bloodstream in proportion to adipose tissue mass (2, 6,
7, 20) and recent energy intake (3, 11, 22, 54). Although
there is increasing evidence that leptin production is
regulated by insulin (21, 46), probably via changes of
adipocyte glucose metabolism (41), the effects of leptin
on insulin secretion are more controversial due to a
number of conflicting reports in the literature. Leptin
acts through specific leptin receptors, which belong to
the class I cytokine receptor family (52). A main site of
action of leptin is the hypothalamus, where it has the
effect of inhibiting food intake and stimulating energy
expenditure (6, 19, 43). However, several studies have
shown that leptin also acts peripherally. For example,
leptin receptors are present in bone marrow and in the
liver (16, 53).
In 1996, Kieffer and collaborators (28) reported that
leptin receptors are also expressed in the insulin-
producing B cells within the pancreatic islets, suggest-
ing that leptin might influence insulin secretion through
a direct action on these cells. This was later confirmed
by Emilsson et al. in 1997 (12) as well as by several
other investigators (9, 13, 32, 42, 44, 51). It is important
to determine the functional role of these receptors in
regulating islet function, because leptin levels are
increased in obese subjects (2, 6, 7, 20). Obese subjects
with reduced insulin sensitivity exhibit a compensatory
hypersecretion of insulin and hyperinsulinemia that
helps to prevent glucose intolerance (33). However, if
hyperleptinemia affects this islet adaptation to reduced
insulin sensitivity, leptin could potentially have a role in
the development of glucose intolerance in obese subjects.
Leptin has been shown to inhibit insulin secretion
from insulin-producing insulinoma cells (15, 32, 56),
isolated rodent (9, 12, 24, 29, 32, 42, 44, 48, 56) and
human (13, 32, 38) islets, the perfused rodent pancreas
(14, 15), and in vivo in mice (32). However, there are
also conflicting reports in the literature. Some studies
using an isolated perfused rat pancreas model found
that leptin did not affect insulin secretion (34–36),
whereas in other studies, leptin was shown to stimulate
insulin secretion in islets and insulinoma cells (8, 49,
51). Therefore, conflicting data exist regarding the
influence of leptin on insulin secretion.
In early 1998, Poitout and collaborators (44) reported
that leptin preferentially inhibits insulin secretion in
the presence of 3-isobutyl-1-methylxanthine (IBMX),
which raises the level of cAMP through a nonspecific
inhibition of phosphodiesterase (PDE) subspecies. These
results supported the previous findings of a potent
inhibitory effect of leptin reported in the presence of the
glucoincretin, glucagon-like peptide-1 (GLP-1; 14, 56).
Furthermore, a recent study has shown that leptin
inhibits insulin secretion by activating the PDE 3B
subspecies of PDE (56), which would reduce the content
of cAMP, thereby preventing specifically the cAMP-
protein kinaseA(PKA)-induced insulin secretion. These
findings led us to the working hypothesis that leptin
preferentially inhibits insulin secretion when cAMP
levels are elevated. In this report, we present experimen-
tal evidence for this hypothesis in the insulin-produc-
ing INS-1 rat insulinoma cell line. This cell line was
used because it retains morphologically differentiated
characteristics compared with other cell lines and also
shows a marked insulinotropic response to glucose and
to increases of the cellular content of cAMP induced by
forskolin (4).
METHODS
Cells. INS-1 cells [derived from an X-ray-induced insuli-
noma in the rat exhibiting characteristics resembling the
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normal B cell (4); cells were a kind gift from Professor Claes
Wollheim, Geneva, Switzerland] were cultured at 37°C in
humidified 5% CO2 in air in RPMI 1640 medium (GIBCO
BRL, Paisley, UK) supplemented with 10% fetal calf serum,
100 U/ml penicillin, 100 µg/ml streptomycin (all Kebo Labora-
tory, Spa˚nga, Sweden), and 50 µM b-mercaptoethanol (GIBCO)
(4). Cells were subcultured every 7–10 days by trypsination,
and the medium was changed after each subculture and
thereafter every fourth day. Cells were used for experiments
after reaching confluency at 7–10 days after subculture. The
cells were used in experiments in passage numbers 76–84.
Insulin secretion experiments. Cells were seeded into 24-
well plates (Nunc, Roskilde, Denmark) at a concentration of
0.5 million cells/well and cultured for 48 h. The cells were
then washed twice in HEPES medium containing (in mmol/l)
125 NaCl, 5.9 KCl, 1.28 CaCl2, 1.2 MgCl2, 25 HEPES, and
0.1% human serum albumin (pH 7.36; all Sigma Chemical,
St. Louis, MO) and incubated in a volume of 200 µl with 1
mmol/l glucose for 30 min. Thereafter, the medium was
changed and the cells were incubated in the HEPES medium
supplemented with varying concentrations of glucose, recom-
binant murine leptin (Amgen, Thousand Oaks, CA), synthetic
GLP-1, synthetic ovine pituitary adenylate cyclase activating
polypeptide-38 (PACAP-38; both Peninsula Europe, Mersey-
side, UK), forskolin, IBMX, dibutyryl-cAMP, CCK-8, 12-O-
tetradecanoylphorbol 13-acetate (TPA) (all Sigma), and/or
carbachol (BDH, Poole, UK) according to the protocols. In one
experimental series, leptin (20 nmol/l, which is approxi-
mately 10 times higher than circulating levels of leptin; Ref.
2) was also added during the 30-min preincubation. After 60
min, an aliquot of 150 µl was collected from each well and
centrifuged at 350 g for 5 min. Aliquots of 50 µl were then
stored at 20°C until analysis of insulin by means of a
radioimmunoassay using guinea pig anti-porcine insulin,
mono-125I-insulin, and, as standard, rat insulin (Linco, St.
Charles, MO). Free and bound radioactivity were separated
by use of an anti-IgG (goat anti-guinea pig) antibody (Linco).
Measurements of Ca21. Cytoplasmic Ca21 concentration
([Ca21]cyt) was determined in fura 2-AM-loaded INS-1 cells
according to a previously described protocol (30). In brief,
cells were grown for 4–7 days in RPMI medium supple-
mented as above. After trypsination, cells were recovered for
2 h in 10 ml of RPMI medium supplemented with 10% fetal
calf serum at 37°C in 5% CO2 and were thereafter loaded with
fura 2-AM (1 µmol/l; Sigma) for 45 min. After equilibration for
20 min, 2 ml of the cell suspension (0.5 million cells/ml) were
transferred to a cuvette for measurement of [Ca21]cyt in a
Perkin-Elmer LS-50 spectrophotofluorometer at 37°C. Forsko-
lin and leptin were added at defined time points and re-
mained in the cuvette until the end of the experiment.
Excitation wavelengths were 340 and 380 nm, and the
emission wavelength was 510 nm. Fluorescence maximum
was obtained by adding 0.03% Triton X, and fluorescence
minimum was obtained by adding EGTA in excess at the end
of experiments performed in the absence of albumin. [Ca21]cyt
was calculated according to Grynkiewicz et al. (18).
Measurements of cellular cAMP. INS-1 cells were seeded on
four-well plates (0.5 million cells/well) and cultured for 48 h.
The cells were then washed twice in the HEPES medium and
incubated at 37°C in a volume of 200 µl in the presence of 10
mmol/l glucose and 0.1 mmol/l IBMX with or without the
addition of forskolin and leptin. The incubation was stopped
after 2 min with addition of ice-cold ethanol (final concentra-
tion 65%), and the cells were scraped off with a rubber
policeman. After being washed twice in 65% ice-cold ethanol,
the extracts were centrifuged at 2,000 g at 4°C for 15 min,
transferred to fresh test tubes, evaporated at 60°C under a
stream of nitrogen, and then stored at 220°C until analysis
for protein content by the Lowry method (37) and for cAMP by
radioimmunoassay, using a rabbit antisuccinyl AMP serum,
cyclic 2-succinyl-3-125I-methyl ester as tracer, and cAMP as
standard (Amersham, Amersham, UK). Free and bound
radioactivity were separated by the double antibody tech-
nique. The results are reported as amount of cellular cAMP
divided by amount of cellular protein.
Statistics. The results are reported as means 6 SE. Statis-
tical evaluation of differences between groups was performed
by one-way ANOVA followed by Bonferroni post hoc test or by
two-tailed Student’s t-test for unpaired comparison. P , 0.05
was considered significant.
RESULTS
Glucose-stimulated insulin secretion. Figure 1 shows
that insulin secretion from INS-1 cells incubated for 60
min was stimulated by glucose in a concentration-
dependent manner with a maximal stimulation at 10
mmol/l. The addition of leptin at a concentration of 20
nmol/l, added either during the 60-min incubation only
or also during the 30-min preincubation period, had no
effect on glucose-stimulated insulin secretion. Further-
more, leptin at concentrations ranging from 0.1 to 100
nmol/l had no influence on the insulin secretory re-
sponse to glucose at a fixed glucose concentration of 10
mmol/l (Fig. 2). Furthermore, when the cells were
incubated in the presence of a nonstimulatory glucose
concentration (3 mmol/l) together with leptin at 0.5, 1,
5, 10, 20, or 50 nmol/l, no influence of leptin was
observed on insulin secretion (data not shown in Fig. 2).
Hence, over a wide range of concentrations, leptin had
no effect on glucose-stimulated insulin secretion from
INS-1 cells whether administered with glucose during
the incubation only or during the preincubation period
as well.
Fig. 1. Insulin secretion from INS-1 cells cultured for 60 min in
presence of different concentrations of glucose with or without
addition of leptin (20 nmol/l) during incubation period only or during
30-min preincubation period as well. Means 6 SE are shown, n 5 24
wells examined in 4 different experiments.
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GLP-1- and PACAP-38-induced insulin secretion. Both
GLP-1 (100 nmol/l) and PACAP-38 (100 nmol/l) mark-
edly potentiated glucose (10 mmol/l)-stimulated insulin
secretion from INS-1 cells (Fig. 3). Leptin (20 nmol/l)
significantly inhibited insulin secretion stimulated by
GLP-1 by 58% and by PACAP by 46%, suggesting that a
signaling pathway activated by these peptide hor-
mones, but not by glucose, is targeted by leptin.
Forskolin- and cAMP-induced insulin secretion. Be-
cause the insulinotropic action of both GLP-1 and
PACAP-38 has been thought to largely rely on forma-
tion of cAMP (1, 10, 17, 30, 50), we examined the
influence of leptin (20 nmol/l) on insulin secretion
stimulated by forskolin (2.5 µmol/l), which activates
adenylate cyclase, or dibutyryl-cAMP (1 mmol/l), which
mimics the effects of endogenously produced cAMP.
Both forskolin and dibutyryl-cAMP markedly stimu-
lated insulin secretion in INS-1 cells and leptin inhib-
ited insulin secretion stimulated by these agents by 34
and 35%, respectively (Fig. 4). This result suggests that
leptin inhibits insulin secretion under conditions when
intracellular cAMP is elevated.
Glucose-stimulated insulin secretion in the presence
of IBMX. The nonspecific PDE inhibitor IBMX is known
to increase the cellular content of cAMP and thereby
potentiate glucose-stimulated insulin secretion by exag-
gerating the PKA pathway (25, 39). Leptin (20 nmol/l)
inhibited insulin secretion induced by IBMX (100 µmol/l)
in the presence of 10 mmol/l glucose by 48% (Fig. 4),
further suggesting that an increased level of intracellu-
lar cAMP is required to detect an insulinostatic effect of
leptin in INS-1 cells.
Carbachol-, TPA-, and CCK-8-stimulated insulin se-
cretion. To determine whether the inhibition by leptin
of insulin secretion is specific for the cAMP-PKA path-
way, we also examined the influence of leptin on insulin
secretion in the presence of agents known to target
protein kinase C (PKC), i.e., the cholinergic agonist
carbachol and the phorbol ester TPA (25). Leptin (20
nmol/l) did not affect carbachol (100 µmol/l)- or TPA (1
µmol/l)-stimulated insulin secretion (Fig. 5). The effects
of the COOH-terminal octapeptide of the gut hormone
cholecystokinin on insulin secretion were also exam-
ined, because this gut hormone is known to stimulate
insulin secretion largely through activation of PKC
(26). However, we found that CCK-8 did not stimulate
insulin secretion in INS-1 cells when incubated over a
wide range of doses (0.1 nmol/l–1 µmol/l) at 10 mmol/l
glucose (data not shown). Therefore, the combination of
CCK-8 and leptin was not examined.
Cytoplasmic Ca21. In addition to activation of PKA,
formation of cAMP is also known to stimulate exocyto-
Fig. 2. Insulin secretion from INS-1 cells cultured for 60 min in
presence of 10 mmol/l glucose and different concentrations of leptin.
Means 6 SE are shown, n 5 16 wells examined in 4 different
experiments.
Fig. 3. Insulin secretion from INS-1 cells cultured for 60 min in
presence of 3 or 10 mmol/l glucose with or without addition of
glucagon-like peptide (GLP)-1 (100 nmol/l) or pituitary adenylate
cyclase activating polypeptide (PACAP)-38 (100 nmol/l) and/or leptin
(20 nmol/l). Means 6 SE are shown, n 5 18 wells examined in 3
different experiments. Probability level of random difference vs.
glucose control: **P , 0.01.
Fig. 4. Insulin secretion from INS-1 cells cultured for 60 min in
presence of 3 or 10 mmol/l glucose with or without addition of
dibutyryl-cAMP (dbcAMP; 1 mmol/l), 3-isobutyl-1-methylxanthine
(IBMX; 100 µmol/l), or forskolin (2.5 µmol/l) and/or leptin (20 nmol/l).
Means 6 SE are shown, n 5 16 wells examined in 4 different
experiments. Probability level of random difference vs. glucose
control: *P , 0.05, ***P , 0.001.
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sis by increasing [Ca21]cyt (17). To determine whether
leptin inhibits forskolin-induced increase in [Ca21]cyt in
INS-1 cells, fura 2-AM-loaded cells were used. In the
presence of 10 mmol/l glucose, forskolin (2.5 µmol/l)
increased [Ca21]cyt. However, leptin (20 nmol/l) did not
affect either this increase or the baseline [Ca21]cyt (Fig.
6). Similarly, inclusion of leptin (20 nmol/l) during the
45-min loading period did not affect the subsequent
forskolin-induced increase in [Ca21]cyt. Finally, leptin
did not affect the increase in [Ca21]cyt induced by
depolarization with KCl (20 mmol/l; data not shown).
Cellular cAMP. To examine whether the inhibition by
leptin of insulin secretion stimulated by agents raising
cAMP is due to degradation of formed cAMP, INS-1
cells were incubated in the presence of forskolin (2.5
µmol/l) with or without addition of leptin (20 nmol/l) at
10 mmol/l glucose. It was found that the cellular cAMP
content in controls incubated at 10 mmol/l glucose
without addition of forskolin or leptin was 45.9 6 4.2
pmol/mg protein. This was raised by addition of forsko-
lin to 86.4 6 4.3 pmol/mg protein (P , 0.001). The
cellular content of cAMP after combined addition of
forskolin and leptin was 88.5 6 5.8 pmol/mg protein,
which is not significantly different from that after
incubation with forskolin alone. Hence, leptin does not
affect the increased cellular content of cAMP induced
by forskolin, suggesting that under these conditions,
leptin does not stimulate the degradation of cAMP.
DISCUSSION
In this study we found that incubation with leptin did
not affect glucose-stimulated insulin secretion from rat
insulinoma INS-1 cells when examined over a wide
range of leptin concentrations and with a range of
glucose levels. In contrast, leptin inhibited insulin
secretion induced by agents that increase the intracel-
lular levels of cAMP. Therefore, the present study
provides novel evidence that leptin specifically inhibits
insulin secretion when cellular cAMP is elevated using
a variety of interventions that activate or potentiate
the PKA signal transduction pathway.
To exclude the possibility that the failure of leptin to
inhibit the insulinotropic response to glucose was due
to a short incubation period (see Ref. 45), in one series
of experiments leptin was included in the 30-min
preincubation period as well, but again no effect on
insulin secretion was observed. Moreover, we did not
detect any influence of leptin on [Ca21]cyt in the pres-
ence of 10 mmol/l glucose or on the cellular content of
cAMP in the presence of glucose and forskolin. These
results suggest that although leptin receptors are
expressed in INS-1 cells (15), leptin does not interact
with the signaling pathways regulating the insulinotro-
pic action of glucose in this cell line. Previous studies
have shown a weak inhibitory influence of leptin on
insulin secretion in HIT-T15 cells (leptin 2 nmol/l;
glucose 11 mmol/l; 56), in bTC-6 cells (leptin 10 nmol/l;Fig. 5. Insulin secretion from INS-1 cells cultured for 60 min in
presence of 3 or 10 mmol/l glucose with or without addition of
carbachol (100 µmol/l), 12-O-tetradecanoylphorbol 13-acetate (TPA; 1
µmol/l), and/or leptin (20 nmol/l). Means 6 SE are shown, n 5 18
wells examined in 3 different experiments.
Fig. 6. Cytoplasmic concentration of calcium ([Ca21]cyt) in fura
2-AM-loaded INS-1 cell suspensions at 10 mmol/l glucose with or
without presence of leptin (20 nmol/l; present during entire experi-
ment including 2-h loading period preceding measurement). At 300 s,
forskolin (2.5 µmol/l) was added. In A means 6 SE are shown (n 5 4
for each series), and in B typical traces are shown.
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glucose 5.5 mmol/l; 32), and in RINm5F cells (leptin 1
nmol/l; glyceraldehyde 15 mmol/l; 32). In contrast,
leptin (0.7 and 7 nmol/l) stimulated insulin secretion in
another study in HIT-T15 cells (glucose 7 mmol/l; 49).
This variable and usually weak influence of leptin on
insulin secretion suggests that leptin mainly influences
signaling pathways other than those activated by glu-
cose (or glyceraldehyde) in these cell lines. This is
consistent with results in normal CD1 mouse islets, in
which leptin had no effect at 16.7 mmol/l glucose but
clearly inhibited insulin secretion if IBMX was added to
the media (44). This is also similar to one study in islets
isolated from wild-type littermates of ob/ob mice, in
which leptin (20 and 100 nmol/l) did not inhibit glucose
(20 mmol/l)-induced insulin secretion (9). However,
another study has shown that leptin (10 nmol/l) inhib-
its glucose (16.7 mmol/l)-stimulated insulin secretion
by 29% in wild-type ob/ob littermates (12).
Conflicting results have also been obtained in studies
of glucose-stimulated insulin secretion in normal rat
islets. Ishida and collaborators (24) demonstrated inhi-
bition by leptin (8 nmol/l) at 5.5 but not at 11.1 mmol/l
glucose (24); Kulkarni et al. (32) found inhibition by
leptin (0.1 nmol/l) at 8 mmol/l glucose; and Seufert et al.
(48) demonstrated inhibition by leptin (6.25 nmol/l) at
5.6 mmol/l glucose, whereas Ookuma et al. (42) showed
inhibition by leptin (2.5 nmol/l) at high glucose (16.7
mmol/l). In contrast, Poitout and collaborators (44) did
not find any influence of leptin (0.7 nmol/l) on glucose
(16.7 mmol/l)-stimulated insulin secretion from normal
rat islets and Ceddia and collaborators (8) demon-
strated a stimulatory action of leptin (50 nmol/l) on
insulin secretion in the presence of 2.8 or 5.6 mmol/l
glucose in rat islets. Together, all of the studies examin-
ing the effects of leptin on glucose-stimulated secretion
suggest that in some preparations leptin can inhibit
glucose-stimulated insulin secretion, whereas in many
others, leptin receptor activation does not appear to
target the signaling pathways regulating glucose-
stimulated insulin secretion. In a few other studies,
leptin has even been found to stimulate insulin secre-
tion.
Compared with the lack of a pronounced and consis-
tent effect of leptin on glucose-stimulated insulin secre-
tion from normal islets or insulin-producing cells, a
marked inhibitory influence has been observed in islets
isolated from ob/ob mice (9, 12, 29, 32), which do not
produce biologically active leptin due to a mutation in
the leptin gene (55). These results suggest that B cells
from ob/ob mice may be more sensitive to the insulino-
static effects of exogenous leptin. This idea is supported
by reports that the altered insulin secretion and islet
function due to leptin deficiency are normalized by
exogenous leptin (47).
Although most studies report an inhibitory action of
leptin on insulin secretion, no general agreement exists
regarding the mechanism of such an action. For ex-
ample, one study in islets from ob/ob mice suggested
that leptin acts primarily by opening the ATP-regu-
lated K1 channels, which would close voltage-sensitive
Ca21 channels and reduce the [Ca21]cyt, thereby inhibit-
ing the process of exocytosis (29). In contrast, another
study of insulin-producing INS-1 cells revealed that,
although leptin reduced [Ca21]cyt, it did not affect
membrane potential, suggesting that leptin works inde-
pendently from K1 channel activity (15). Other studies
have shown that in isolated rat islets, leptin preferen-
tially inhibits insulin secretion stimulated by PKC,
activated either by acetylcholine (9) or a phorbol ester
(42), suggesting a distally located action of leptin
related to PKC-induced exocytosis. Yet other studies
have demonstrated that leptin inhibits insulin secre-
tion from rat islets and hamster insulinoma HIT-T15
cells induced by GLP-1 (14, 56). GLP-1 is thought to act
primarily through receptors coupled to adenylate cy-
clase and increased intracellular cAMP (1, 10, 17). In
another study, however, leptin did not inhibit GLP-1-
induced insulin secretion in mouse islets (9). Collec-
tively, these conflicting results suggest that the mecha-
nism of the inhibitory action of leptin on insulin
secretion is likely to differ in different types of insulin-
producing cells. These differences may be ascribed to
inherent characteristics of the cell types and/or to
methodological differences between laboratories.
In contrast to the absence of an inhibitory action of
leptin on glucose-stimulated insulin secretion, we found
that leptin consistently and significantly inhibited insu-
lin secretion stimulated by GLP-1, PACAP, forskolin,
dibutyryl-cAMP, and IBMX. The similarity between the
insulinotropic actions of these agents is that they all
induce an increase in the intracellular content of
cAMP: GLP-1, PACAP, and forskolin by stimulating
adenylate cyclase and inducing formation of cAMP (1,
10, 17, 30, 50), dibutyryl-cAMP by being a membrane-
penetrable analog of cAMP, and IBMX by reducing the
degradation of cAMP through stimulation of PDE (25,
39). Therefore, in INS-1 cells, leptin appears to inhibit
insulin secretion when the intracellular content of
cAMP is elevated. This is similar to a recent study in
isolated rat islets, in which leptin did not inhibit
glucose-stimulated insulin secretion unless IBMX was
included in the medium (44). Two possible mechanisms
might explain this action of leptin. One explanation is
that leptin reduces the cellular content of cAMP, for
example by activating PDE. A second explanation is
that leptin inhibits the downstream pathway initiated
by activation of PKA. The former explanation would be
supported by a recent study showing that leptin acti-
vates a specific subspecies of PDE, PDE3B, reducing
cellular cAMP content in cultured neonatal rat islet
monolayers and in HIT-T15 cells (56). However, we
believe that the latter explanation is more likely be-
cause we found that leptin did not reduce the content of
cAMP after stimulation with forskolin. It has also
previously been shown that leptin does not affect the
cellular content of cAMP in INS-1 cells, although leptin
inhibits GLP-1-induced insulin secretion (14). Further-
more, leptin also inhibited the insulin response to
IBMX, which nonspecifically inhibits all PDE subspe-
cies, thereby precluding any specific action by leptin on
these enzymes. The downstream action of activation of
PKA involves phosphorylation of channels inhibiting
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ATP-sensitive K1 channels and/or activating Ca21 chan-
nels, allowing a net uptake of calcium in addition to
phosphorylation of exocytotic proteins (23, 25). We
found that the peptide did not affect [Ca21]cyt, either
under baseline conditions or after increasing [Ca21]cyt
after stimulation with forskolin. These results there-
fore suggest that leptin inhibits insulin secretion at a
distal site after activation of PKA and that this site is
also distal to changes in [Ca21]cyt.
Our finding that leptin did not reduce [Ca21]cyt in the
presence of 10 mmol/l glucose is at variance with the
previous study by Fehmann and collaborators (15) who
reported that leptin (10 nmol/l) reduced [Ca21]cyt in
INS-1 cell suspensions (15). This discrepancy is prob-
ably explained by the difference in methodology used,
because in their study the cells were incubated in a
culture medium containing serum, whereas our study
was performed keeping the cells in a well-defined
serum-free incubation medium. This resulted in marked
difference in baseline levels of [Ca21]cyt (<190 vs. <75
nmol/l in our present study). Hence, it is possible that
leptin could reduce levels of [Ca21]cyt that have been
elevated by factors included in the serum-containing
medium. Our study shows, however, that under condi-
tions of raised glucose and introduction of forskolin,
when leptin inhibits insulin secretion, the [Ca21]cyt is
unaffected by leptin.
In addition, we found that leptin did not affect the
insulinotropic action of carbachol and TPA. Both these
agents stimulate insulin secretion through activation
of PKC (25). Thus these results suggest that, in INS-1
cells, leptin does not interact with this signaling path-
way. This confirms a recent study in normal mouse
islets, showing that leptin does not affect insulin secre-
tion stimulated by acetylcholine or a phorbol ester (9).
In this study it was also observed that in ob/ob mice
islets, which exhibit increased sensitivity to agents
activating PKC, leptin also suppresses the insulinotro-
pic response to acetylcholine or the phorbol ester (9).
This suggests that leptin has the capacity to inhibit
PKC-induced insulin secretion, but this is only ob-
served under abnormal conditions, such as in islets
from ob/ob mice that have experienced chronic leptin
deficiency and have increased sensitivity to PKC.
In our study, we also intended to use CCK-8, which
has been demonstrated to stimulate insulin secretion
in isolated rat islets through activation of PKC (26).
However, CCK-8 did not stimulate insulin secretion in
this cell line, which is similar to our recent experience
with the RINm5F cell line (27). Hence, although CCK
receptors are expressed (27), signaling pathways acti-
vated by CCK receptors seem not to be targeted in
insulinoma cells.
On the basis of the results presented in this study, we
conclude that leptin inhibits insulin secretion in INS-1
cells when the intracellular content of cAMP is ele-
vated. A tentative model for mechanism of action of
leptin is that leptin reduces the action of the cAMP-
PKA signal transduction pathway, which may impair
the function of proteins located further downstream in
the signal transduction pathway that are phosphory-
lated by PKA (25). This mechanism of leptin is different
from that reported in other insulin producing cells (see
above). It is likely that the inherent characteristics of
insulin-producing cells, being of different origins and
having different signaling characteristics, may help to
explain discrepancies in the actions of leptin on insulin
secretion. In addition, the extrinsic influence of the
incubation conditions is another variable that needs to
be considered.
Perspectives
Previous studies on the action and mechanism of
leptin on insulin secretion have yielded mixed results,
and this area of investigation remains controversial.
Nonetheless, the main body of evidence suggests that
leptin inhibits insulin secretion. We used the clonal
cells, i.e., INS-1 cells, to examine whether the effect of
leptin is dependent on primary mechanisms driving
insulin secretion. We found that leptin inhibits insulin
secretion under conditions when the cellular content of
cAMP is elevated, but not when insulin secretion is
stimulated by glucose alone or by agents that activate
PKC. Because leptin did not reduce the cAMP content
after stimulation with forskolin, it is suggested that in
this cell line leptin inhibits insulin secretion by inhibit-
ing the cAMP-PKA signaling pathway and not by
activating the PDEs. However, more work is required
to dissect the mechanisms in detail, and to determine
the physiological relevance of leptin interactions with
insulin secretion.
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